Abstract
National Pharmacovigilance Systems (PVS) manage health risks and identify, assess, and act to minimize them, contributing to adequate use of medicines, patient safety, and improved quality of care. Fast-track drug registration, which has become increasingly frequent, hinders assessment of the efficacy and safety of new drugs, adding difficulties to current regulation and health protection. The article applies indicators proposed by the World Health Organization to analyze the National PVS of Portugal and Brazil. Brazil's PVS was established later than that of Portugal, generates fewer safety signals, has a lower notification rate for suspected adverse drug events (ADEs), and displays difficulty in producing and disseminating information to health professionals and the population. Portugal has the advantage of being a member state of the European Medicines Agency. The article also suggests that the differences are related to the political and social context that hinders the implementation of public policies and compromises the effectiveness of the Brazilian PVS. Challenges for PVS include awareness-raising of health professionals, the adoption of methods to complement voluntary notification, pharmacovigilance of biological and g...Continue Reading
References
Jul 11, 1998·Cadernos de saúde pública·S Rozenfeld
Apr 15, 1999·Cadernos de saúde pública·P S Arrais
Nov 11, 2003·Revista da Escola de Enfermagem da U S P·Margaret Lunney
Mar 28, 2008·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Maria T HerdeiroAdolfo Figueiras
Jan 10, 2009·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Elena Lopez-GonzalezAdolfo Figueiras
Jan 19, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Shanthi N PalSten Olsson
Jul 31, 2013·European Journal of Pharmacology·Christine C Gispen-de Wied, Hubertus G M Leufkens
Nov 28, 2013·Journal of Clinical Epidemiology·Terry HainesElizabeth Skinner
Mar 15, 2014·Revista da Escola de Enfermagem da U S P·Cintia Hitomi YamashitaMaria Amélia de Campos Oliveira
Mar 15, 2014·Revista da Escola de Enfermagem da U S P·Etelvaldo Francisco Rego SousaMonika Wernet
Jun 12, 2014·Revista da Escola de Enfermagem da U S P·Luciana Barros de Moura NeivaMaria de Fatima Fernandes Vattimo
Jul 31, 2014·Revista da Escola de Enfermagem da U S P·Rosemary Sadami Arai Shinkai
Jul 31, 2014·Revista da Escola de Enfermagem da U S P·Mariana Rotta BonfimHenrique Luiz Monteiro
Jan 30, 2015·Revista da Escola de Enfermagem da U S P·Sonia Portella de AbreuMárcia Galan Perroca
May 7, 2015·The New England Journal of Medicine·Ameet SarpatwariAaron S Kesselheim
Sep 8, 2015·European Journal of Internal Medicine·Rita BanziSilvio Garattini
May 5, 2017·BMJ : British Medical Journal·Alison M PeaseJoseph S Ross
May 26, 2017·The New England Journal of Medicine·Walid F Gellad, Aaron S Kesselheim
Jul 25, 2017·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Aniello SantoroPeter Arlett
Dec 1, 1978·Revista da Escola de Enfermagem da U S P·Wanda de Aguiar Horta, Célia Pires de Araújo
Aug 1, 1978·Revista da Escola de Enfermagem da U S P·Dirce Trevisi Prado NovaesMaria Lúcia Pimentel de Assis Moura
Aug 18, 2017·Expert Opinion on Drug Safety·Adalton RibeiroAlbert Figueras
Oct 13, 2017·Clinical Pharmacology and Therapeutics·Anne Vinther Morant, Henrik Tang Vestergaard
Jan 11, 2018·Therapeutic Advances in Drug Safety·Andrew BatePatrick Caubel
Jul 19, 2018·Ciência & saúde coletiva·Eleonor Minho ConillErnesto Báscolo
Jul 19, 2018·Ciência & saúde coletiva·Cristiani Vieira Machado